Decentralized Clinical Trials
European Medicines Agency
In-Vitro Diagnostic Regulation
Rare Disease Trials
Research & Development
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. We intend to use the funds to invest in solutions that actively engage patients(...)
Alira Health Strengthens its Growth Strategy with a $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
We Announce our Role as Strategic Advisor to Benvic in the Acquisition of Luc & Bel
We are proud to announce our role as strategic advisor to Benvic in the acquisition of Luc & Bel.
We Announce our Role as Advisor to Sagard NewGen
We are pleased to announce our role as Advisor to Sagard NewGen for the equity investment in Laboratoires Delbert. This recent capital raise of €40m supports the company’s growth(...)
We Announce our Role as Exclusive Strategic Advisor to AGC Biologics in its Acquisition of MolMed SpA
We are proud to announce our role as strategic advisor to AGC Biologics, a leading global biopharmaceutical contract development, and manufacturing organization, in their acquisition(...)
We Announce our Role as a Transaction Advisor to Daiichi Sankyo on the Sale of LOPRESSOR®, ICAZ®, and MIOREL® to SIT Laboratorio Farmaceutico (DESMA HC Group)
Daiichi Sankyo France /(hereafter, Daiichi Sankyo) and SIT Laboratorio Farmaceutico (DESMA HC Group) are pleased to announce the acquisition of LOPRESSOR®, ICAZ® and MIOREL® by SIT(...)
Alira Health Welcomes Romain Finas, Vice President, Real-World Evidence
Alira Health is excited to welcome Romain Finas as our new Vice President, Real-World Evidence. Based in Paris, France, Romain brings deep expertise in real-world data, healthcare workflow(...)
Latest from Alira Health
We are pleased to announce that we will be sponsoring and attending DPHARM, a unique event focused on the latest innovations that modernize clinical trials.
DTx France 2022
We are pleased to announce that we will be joining as speakers and exhibitors at DTx France 2022. This hybrid event will focus on the latest DTx trends, regulatory framework, market(...)
Advanced Wound Care Summit
Join us at the Advanced Wound Care Summit July 13 – 14 in Boston.
Partners in the Continuum of Drug Development
Listen to the new Empowered Patient Podcast with Karen Jagoda as Gabriele Brambilla, Alira Health CEO, discusses novel approach using technology services to actively engage and partner(...)
The Promise and Reality of NGTs
Listen to the episode “The Promise and Reality of Next Generation Therapies".
Webinar Replay: What You Should Know About MDR Best Practices, Including PMCF
Discover the major changes introduced by the MDR, including the post-market requirements, and especially the Post-Market Clinical Follow-up (PMCF).
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2
The last two years have brought forward tremendous advances in the development of prophylactic and therapeutic approaches for the treatment of SARS-CoV-2 infections.
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.